For important risk and disclaimer information, Click here.

Industry

Deep Tech

Company Type

Alternative Investments

Size

$50 Million

Investment Type

Debt/Equity

For additional information, please contact:
Doug Jendras | Managing Director
(203) 501-7667

Overview

IP3 Technologies, a Houston Texas Deep Tech company, is seeking $50MM in equity/debt to fund cutting-edge optimization and out-licensing of patent protected intellectual property (IP) that surpass technological benchmarks

Worldwide royalty payments made for the use of intellectual property in 2023 reached US$528 billion


Intellectual property makes up 90% of the value of S&P 500 (approx. $35 trillion)


PWC audit of the revenue model and business methodology of the late-stage portfolio (5 assets) and excluding anti-infective 013 demonstrates a 2026 projected $31.75MM EBITDA and a current forward cashflow (XNPV) modelled using a 30% discount rate to provide a valuation range of $500MM to $750MM*

Through advanced science and engineering innovations IP3T brings disruptive new products to market that surpass technological benchmarks and push the boundaries of current technology.

IP3 uses a diversified, agnostic market sector criteria for intellectual property


Current portfolio includes wide neck packaging, covert nano barcode, high temperature heat and fire insulation, analytical identification system, antimicrobial additive and anti-infective


IP risks are mitigated by specialist IP & legal insurance and third-party royalty audits

* A detailed financial model with assumptions and scenario analysis functionality is available upon request. Target returns are presented solely for the purpose of providing insight into the company’s objectives, detailing anticipated risk and reward characteristics, and establishing a benchmark for future evaluation of performance. Target returns are not a predictor, projection or guarantee of future performance. There can be no assurance that these targets will be met. There is no guarantee as to the company’s future performance or the adequacy of the methodology used for estimating future returns. Target returns should not be used as a primary basis for an investor’s decision to invest. Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment.

Opportunity

Royalty income, including royalty-related income and intellectual property income, has an attractive risk-return profile


Limited exposure to the operational risks of the licensee business while maintaining benefits of revenue growth of the product/technology


Royalty income is typically revenue-based and able to benefit from inflationary environments as they are neither capital intensive nor exposed to input costs from production


Long term royalty income generation due to favorable patent protection laws


Royalty income should be immune from risks and fluctuations in bond and equity markets


Ability to capitalize the individual royalty streams by selling to pension and sovereign wealth funds

Strategy

Intellectual property origination focused on large volume/value markets in diverse sectors such as Military & Aerospace, Packaging & Global Supply Chains, Electric Vehicles & Fire Safety, Construction & Infrastructure, Healthcare & Pharmaceutical


Agnostic market sector criteria for intellectual property ensures risk diversification


Innovative products & technologies developed are ready for commercialization by a licensee with minimal capital investment

The out-licensing program primarily targets major corporations to ensure high quality revenue streams


Consistently replenish a diversified portfolio to generate new revenue streams


Layering of current & future individual royalty streams has a compounding effect

Solution

IP asset portfolios include patents, patent applications and trade secret technologies


Current portfolio includes wide neck packaging, covert nano barcode, high temperature heat & fire insulation, analytical identification system, antimicrobial additive and anti-infective


Outsourced business model to minimize capital expenditures and staffing requirements

Management

Henry Guy Stevens – Chairman & Director


Henry’s focus is innovation and invention with a 35+ year career in research & management. He has amassed a wealth of expertise in the technological development process with over 200 patents granted, safeguarding an array of innovations, for products spanning sectors from logistics & packaging to software & consumer products and their relevant licensing. His endeavours have led him to secure patents, ranging from pallet tracking software to polymer processing methodologies, tablet-forming apparatuses, detergent packaging, medical disposables etc. Has more recently undertaken the origination and optimization of the intellectual property pipeline acquired by IP3T. Previously managing commercial interests in multiple jurisdictions including United Kingdom, Middle East, Bermuda, SE Asia and USA.

Dr. Laura Harman – Chief Scientific Ofiicer


Laura obtained an Undergraduate degree in Genetics and Immunology from the University of Aberdeen and a Doctorate from the University of Cambridge, specializing in Viral Immunology. Early career focused on medical R&D in academic or commercial environments in areas ranging from human cancer diagnostics, dementia, immune system regulation, human vaccine development and anti-infectives. Joining IP3S in Oxford England, focus has turned to innovation and the development of technologies that bring significant economic and environmental benefit to the global market and now leading the scientific function at IP3T.

Specific Risks

  • Patent Litigation – intellectual property (IP) insurance typically serves two purposes — it can help companies cover litigation costs related to the enforcement or defense of patents, trademarks or copyrights, and it can help protect policyholders from patent infringement claims brought against them
  • Patent Infringement – a company producing/selling a product which infringes on the rights granted under the patent. Legal action is necessary beginning with cease-and-desist letters or sign a license progressing to court action
  • Unpaid Royalties – the understating of actual production/sales to reduce royalty payments. Royalty agreements have clauses allowing licensors to use 3rd party auditors to check production/sales records and companies provide the onsite audit services
  • Regulatory (EPA/FDA) approvals may take longer than expected
  • Licensing negotiations may take longer than projected
  • Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
Learn More About IP3 Technologies

Thank you for your interest in IP3 Technologies.

Please fill out your information and we will contact you shortly with more information on this opportunity.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending